Effect of a 5-HT1A receptor agonist, flesinoxan, on the extracellular noradrenaline level in the hippocampus and on the locomotor activity of rats

Akira Suwabe, Masaharu Kubota, Masanobu Niwa, Kazuhiko Kobayashi, Shigenobu Kanba

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

We have studied effects of 5-hydroxytryptamine 1A (5-HT1A) receptor-selective compounds on the extracellular noradrenaline (NA) level in the hippocampus of rats using microdialysis and on their locomotor activity. A selective 5-HT1A) receptor agonist, flesinoxan (5 mg/kg, i.p.) increased the extracellular NA level in the hippocampus, and increased the locomotor activity. Both responses were blocked by pretreatment with a 5-HT1A receptor antagonist, WAY100635 (1 mg/kg, i.p.) and an α2 adrenoceptor agonist, clonidine (50 μg/kg, i.p.). Bilateral intrahippocampal injection of flesinoxan (200 nmol in 2 μl, respectively) increased the locomotor activity of rats and the intrahippocampal perfusion of flesinoxan (1 mM, 2 μl/min) increased the extracellular NA level in the hippocampus. Bilateral intrahippocampal injections of a small amount of WAY100635 (0.1 nmol in 2 μl, respectively) blocked the flesinoxan (5 mg/kg, i.p.)-induced hyperactivity. Flesinoxan (5 mg/kg, i.p.) did not significantly influence the level of serotonin or its major metabolite in the hippocampus, or dopamine or its metabolites in the striatum. In conclusion, these behavioral as well as pharmacological results indicate that postsynaptic 5-HT1A receptor activation by flesinoxan increase the extracellular NA level in the hippocampus, which may be the cause of the increase of the locomotor activity.

Original languageEnglish
Pages (from-to)393-401
Number of pages9
JournalBrain Research
Volume858
Issue number2
DOIs
Publication statusPublished - Mar 10 2000

Fingerprint

Receptor, Serotonin, 5-HT1A
Locomotion
Hippocampus
Norepinephrine
Injections
Microdialysis
Clonidine
Adrenergic Receptors
flesinoxan
Dopamine
Serotonin
Perfusion
Pharmacology

All Science Journal Classification (ASJC) codes

  • Neuroscience(all)
  • Molecular Biology
  • Clinical Neurology
  • Developmental Biology

Cite this

Effect of a 5-HT1A receptor agonist, flesinoxan, on the extracellular noradrenaline level in the hippocampus and on the locomotor activity of rats. / Suwabe, Akira; Kubota, Masaharu; Niwa, Masanobu; Kobayashi, Kazuhiko; Kanba, Shigenobu.

In: Brain Research, Vol. 858, No. 2, 10.03.2000, p. 393-401.

Research output: Contribution to journalArticle

Suwabe, Akira ; Kubota, Masaharu ; Niwa, Masanobu ; Kobayashi, Kazuhiko ; Kanba, Shigenobu. / Effect of a 5-HT1A receptor agonist, flesinoxan, on the extracellular noradrenaline level in the hippocampus and on the locomotor activity of rats. In: Brain Research. 2000 ; Vol. 858, No. 2. pp. 393-401.
@article{caf0fa1593e4482394871ca43483ac58,
title = "Effect of a 5-HT1A receptor agonist, flesinoxan, on the extracellular noradrenaline level in the hippocampus and on the locomotor activity of rats",
abstract = "We have studied effects of 5-hydroxytryptamine 1A (5-HT1A) receptor-selective compounds on the extracellular noradrenaline (NA) level in the hippocampus of rats using microdialysis and on their locomotor activity. A selective 5-HT1A) receptor agonist, flesinoxan (5 mg/kg, i.p.) increased the extracellular NA level in the hippocampus, and increased the locomotor activity. Both responses were blocked by pretreatment with a 5-HT1A receptor antagonist, WAY100635 (1 mg/kg, i.p.) and an α2 adrenoceptor agonist, clonidine (50 μg/kg, i.p.). Bilateral intrahippocampal injection of flesinoxan (200 nmol in 2 μl, respectively) increased the locomotor activity of rats and the intrahippocampal perfusion of flesinoxan (1 mM, 2 μl/min) increased the extracellular NA level in the hippocampus. Bilateral intrahippocampal injections of a small amount of WAY100635 (0.1 nmol in 2 μl, respectively) blocked the flesinoxan (5 mg/kg, i.p.)-induced hyperactivity. Flesinoxan (5 mg/kg, i.p.) did not significantly influence the level of serotonin or its major metabolite in the hippocampus, or dopamine or its metabolites in the striatum. In conclusion, these behavioral as well as pharmacological results indicate that postsynaptic 5-HT1A receptor activation by flesinoxan increase the extracellular NA level in the hippocampus, which may be the cause of the increase of the locomotor activity.",
author = "Akira Suwabe and Masaharu Kubota and Masanobu Niwa and Kazuhiko Kobayashi and Shigenobu Kanba",
year = "2000",
month = "3",
day = "10",
doi = "10.1016/S0006-8993(00)01941-7",
language = "English",
volume = "858",
pages = "393--401",
journal = "Brain Research",
issn = "0006-8993",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Effect of a 5-HT1A receptor agonist, flesinoxan, on the extracellular noradrenaline level in the hippocampus and on the locomotor activity of rats

AU - Suwabe, Akira

AU - Kubota, Masaharu

AU - Niwa, Masanobu

AU - Kobayashi, Kazuhiko

AU - Kanba, Shigenobu

PY - 2000/3/10

Y1 - 2000/3/10

N2 - We have studied effects of 5-hydroxytryptamine 1A (5-HT1A) receptor-selective compounds on the extracellular noradrenaline (NA) level in the hippocampus of rats using microdialysis and on their locomotor activity. A selective 5-HT1A) receptor agonist, flesinoxan (5 mg/kg, i.p.) increased the extracellular NA level in the hippocampus, and increased the locomotor activity. Both responses were blocked by pretreatment with a 5-HT1A receptor antagonist, WAY100635 (1 mg/kg, i.p.) and an α2 adrenoceptor agonist, clonidine (50 μg/kg, i.p.). Bilateral intrahippocampal injection of flesinoxan (200 nmol in 2 μl, respectively) increased the locomotor activity of rats and the intrahippocampal perfusion of flesinoxan (1 mM, 2 μl/min) increased the extracellular NA level in the hippocampus. Bilateral intrahippocampal injections of a small amount of WAY100635 (0.1 nmol in 2 μl, respectively) blocked the flesinoxan (5 mg/kg, i.p.)-induced hyperactivity. Flesinoxan (5 mg/kg, i.p.) did not significantly influence the level of serotonin or its major metabolite in the hippocampus, or dopamine or its metabolites in the striatum. In conclusion, these behavioral as well as pharmacological results indicate that postsynaptic 5-HT1A receptor activation by flesinoxan increase the extracellular NA level in the hippocampus, which may be the cause of the increase of the locomotor activity.

AB - We have studied effects of 5-hydroxytryptamine 1A (5-HT1A) receptor-selective compounds on the extracellular noradrenaline (NA) level in the hippocampus of rats using microdialysis and on their locomotor activity. A selective 5-HT1A) receptor agonist, flesinoxan (5 mg/kg, i.p.) increased the extracellular NA level in the hippocampus, and increased the locomotor activity. Both responses were blocked by pretreatment with a 5-HT1A receptor antagonist, WAY100635 (1 mg/kg, i.p.) and an α2 adrenoceptor agonist, clonidine (50 μg/kg, i.p.). Bilateral intrahippocampal injection of flesinoxan (200 nmol in 2 μl, respectively) increased the locomotor activity of rats and the intrahippocampal perfusion of flesinoxan (1 mM, 2 μl/min) increased the extracellular NA level in the hippocampus. Bilateral intrahippocampal injections of a small amount of WAY100635 (0.1 nmol in 2 μl, respectively) blocked the flesinoxan (5 mg/kg, i.p.)-induced hyperactivity. Flesinoxan (5 mg/kg, i.p.) did not significantly influence the level of serotonin or its major metabolite in the hippocampus, or dopamine or its metabolites in the striatum. In conclusion, these behavioral as well as pharmacological results indicate that postsynaptic 5-HT1A receptor activation by flesinoxan increase the extracellular NA level in the hippocampus, which may be the cause of the increase of the locomotor activity.

UR - http://www.scopus.com/inward/record.url?scp=0034628976&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034628976&partnerID=8YFLogxK

U2 - 10.1016/S0006-8993(00)01941-7

DO - 10.1016/S0006-8993(00)01941-7

M3 - Article

C2 - 10708692

AN - SCOPUS:0034628976

VL - 858

SP - 393

EP - 401

JO - Brain Research

JF - Brain Research

SN - 0006-8993

IS - 2

ER -